IP Library › Granted Patent US 12,305,159
Granted Patent B2
US 12,305,159 · App. 18/391,490 · Granted May 20, 2025

Tissue processing apparatus and method for processing adipose tissue

Inventors: William W. Cimino (Louisville, CO); Ramon Llull (Palma de Mallorca, ES); Adam J. Katz (Winston-Salem, NC)
C12M47/04A61K35/32A61L27/00C12M45/02C12M45/05C12N5/0653A61M1/892A61M2202/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,305,159
App. No.
18/391,490
Granted
May 20, 2025
Kind
B2
Abstract

A portable apparatus useful for collection and processing of human biological material, such as adipose or cancellous bone material, to prepare a concentrated product (e.g., stromal vascular fraction). The apparatus has a container with a containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a pellet well for collecting concentrate product in the form of a pellet phase from centrifuge processing. The pellet well is accessible only from above when the apparatus is in an access orientation. Collected pellet phase material may be removed from the pellet well by direct aspiration, without suspending the material in a suspension liquid within the container. Access ports may be configured for access only from above the container. The apparatus may include a tissue collector disposed in the disuse retention volume to engage and collect collagen or other stringy tissue. A method of processing adipose tissue to concentrate leuko stromal vascular cells includes multi-step processing using a portable container.

Claims (44)

1. A method for making a product comprising a delivery composition for administration to a human patient of uncultured stromal vascular fraction cells derived from harvested adipose tissue from the patient, the method comprising:

washing a volume of harvested adipose tissue from the patient within a single-use, portable processing container to prepare washed adipose tissue within the processing container;

after the washing, enzymatically digesting the washed adipose tissue within the processing container, the enzymatically digesting comprising;

preparing a process mixture in the processing container, comprising adding an enzyme-containing digestion medium to the processing container to contact the washed adipose tissue; and

agitating the process mixture to release stromal vascular fraction cells from the washed adipose tissue;

after a retention time following the adding, centrifuging the processing container to form in the processing container a density-separated pellet phase of stromal vascular fraction cell concentrate comprising stromal vascular fraction cells released from the washed adipose tissue during the enzymatically digesting;

after the centrifuging, selectively removing at least a portion of the stromal vascular fraction cell concentrate from the processing container; and

disposing in a syringe a delivery composition comprising a volume of 0.25 milliliter to 2.5 milliliters of the stromal vascular fraction cell concentrate removed from the processing container dispersed in a dispersion medium suitable for administration to the patient.

2. The method of claim 1 , wherein the delivery composition comprises a ratio of a volume of the dispersion medium to the volume of the stromal vascular fraction in a range of from 1:1 to 10:1.

3. The method of claim 1 , wherein the delivery composition comprises a volume of the dispersion medium in a range of from 1 milliliter to 10 milliliters.

4. The method of claim 1 , wherein the volume of the harvested adipose tissue is in a range of from 20 cubic centimeters to 175 cubic centimeters.

5. The method of claim 1 , wherein the centrifuging comprises centrifuging the processing container until the pellet phase of the stromal vascular fraction cell concentrate has a volume in a range of from 0.2 percent to 2 percent of the volume of the harvested adipose tissue.

6. The method of claim 1 , wherein the agitating comprises moving mixing blades through the process mixture in the processing container.

7. The method of claim 6 , wherein the processing container comprises:

an internal containment volume including a tissue retention volume and a filtrate volume;

a filter disposed within an internal containment volume with the tissue retention volume on one side of the filter and the filtrate volume on another side of the filter, with the tissue retention volume and the filtrate volume being in fluid communication through the filter; and

a rotatable mixer, comprising the mixing blades, disposed in the tissue retention volume;

and wherein:

at commencement of the washing the volume of the harvested adipose tissue is disposed in the tissue retention volume and following the washing and at commencement of the enzymatically digesting, the washed adipose tissue is disposed in the tissue retention volume; and

the washing comprises rotating the rotatable mixer in the tissue retention volume to mix adipose tissue and wash liquid in the tissue retention volume.

8. The method of claim 7 , wherein the centrifuging comprises centrifuging the processing container until the pellet phase of the stromal vascular fraction cell concentrate has a volume in a range of from 0.2 percent to 2 percent of the volume of the harvested adipose tissue.

9. The method of claim 8 , wherein the selectively removing comprises aspirating at least the volume of the stromal vascular fraction cell concentrate directly from the pellet phase through an aspiration tube into a fluid receptacle located outside of the processing container.

10. The method of claim 9 , wherein:

during the aspirating the aspiration tube extends through a vertical portion of the filtrate volume, with the vertical portion having a vertical length of at least 0.5 centimeter, a maximum horizontal cross-dimension of no larger than 10 millimeters and a minimum horizontal cross-dimension of no smaller than 1.5 millimeters; and

at least a portion of the pellet phase aspirated through the aspiration tube during the aspirating is disposed in the vertical portion at commencement of the aspirating.

11. The method of claim 10 , wherein the fluid receptacle is pre-loaded with a quantity of the dispersion medium that is present in the fluid receptacle during the aspirating.

12. The method of claim 11 , wherein the volume of the dispersion medium is in a range of from 1 milliliter to 10 milliliters and the delivery composition in the syringe comprises a ratio of a volume of the dispersion medium to the volume of the stromal vascular fraction in a range of from 1:1 to 10:1.

13. The method of claim 12 , comprising:

prior to the washing, performing a lipoplasty procedure on the patient to obtain the harvested adipose tissue from the patient in lipoaspirate;

during the lipoplasty procedure, collecting at least the volume of the harvested adipose tissue in the tissue retention volume of the processing container, wherein the collecting comprises introducing into the tissue retention volume a quantity of the lipoasperate comprising at least the volume of the harvested adipose tissue.

14. The method of claim 13 , wherein the volume of the harvested adipose tissue is in a range of from 20 cubic centimeters to 175 cubic centimeters.

15. The method of claim 1 , wherein after the centrifuging, the method is in the absence of suspending the volume of the stromal vascular fraction cell concentrate in a suspension liquid in the processing container.

16. The method of claim 1 , wherein the selectively removing comprises aspirating at least the volume of the stromal vascular fraction cell concentrate directly from the pellet phase through an aspiration tube into a fluid receptacle located outside of the processing container.

17. The method of claim 16 , wherein:

the delivery composition comprises a volume of the dispersion medium; and

the fluid receptacle is pre-loaded with at least the volume of the dispersion medium that is present in the fluid receptacle during the aspirating.

18. The method of claim 16 , wherein;

the centrifuging comprises preparing multiple density-separated phases in the processing container, the multiple density-separated phases including lower-density material phases above the pellet phase; and

the aspirating is performed without first removing the lower-density material phases from the processing container.

19. The method of claim 16 , wherein the selectively removing comprises:

inserting the aspiration tube from outside to inside the processing container and downwardly inside the processing container into the pellet phase.

20. The method of claim 16 , wherein:

during the aspirating the aspiration tube extends through a vertical portion of an internal containment volume of the processing container, with the vertical portion having a vertical length of at least 0.5 centimeter, a maximum horizontal cross-dimension of no larger than 10 millimeters and a minimum horizontal cross-dimension of no smaller than 1.5 millimeters; and

at least a portion of the pellet phase aspirated through the aspiration tube during the aspirating is disposed in the vertical portion at commencement of the aspirating.

Assignments (2)
CHANGE OF NAME Recorded Oct 7, 2024
From: THE GID GROUP, INC.
To: GID BIO, INC.
Reel/Frame 069118/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: CIMINO, WILLIAM W.; LLULL, RAMON; KATZ, ADAM J.
To: THE GID GROUP, INC.
Reel/Frame 068650/0661 →
Priority Claims (2)
WO PCT/US2013/058292 · Sep 5, 2013 · international
WO PCT/US2014/011152 · Jan 10, 2014 · international
Continuity (5)
Continuation 18077947 · Dec 8, 2022
Continuation 16422737 · May 24, 2019
Division 14915867
Provisional Application 61926148 · Jan 10, 2014
Related Publication 20240279589A1 · Aug 22, 2024
References Cited (142)
US 3854704A · Balas · 1974 [cited by applicant]
US 4438032A · Golde et al. · 1984 [cited by applicant]
US 4820626A · Williams et al. · 1989 [cited by applicant]
US 5035708A · Alchas et al. · 1991 [cited by applicant]
US 5226914A · Caplan et al. · 1993 [cited by applicant]
US 5330914A · Uhlen et al. · 1994 [cited by applicant]
US 5336616A · Livesey et al. · 1994 [cited by applicant]
US 5372945A · Alchas et al. · 1994 [cited by applicant]
US 5409833A · Hu et al. · 1995 [cited by applicant]
US 5443438A · Wright et al. · 1995 [cited by applicant]
US 5486359A · Caplan et al. · 1996 [cited by applicant]
US 5586732A · Yamauchi et al. · 1996 [cited by applicant]
US 5591625A · Gerson et al. · 1997 [cited by applicant]
US 5610074A · Beritashvili et al. · 1997 [cited by applicant]
US 5624840A · Naughton et al. · 1997 [cited by applicant]
US 5688531A · Benayahu et al. · 1997 [cited by applicant]
US 5728739A · Ailhaud et al. · 1998 [cited by applicant]
US 5736396A · Bruder et al. · 1998 [cited by applicant]
US 5786207A · Katz et al. · 1998 [cited by applicant]
US 5811094A · Caplan et al. · 1998 [cited by applicant]
US 5817050A · Klein · 1998 [cited by applicant]
US 5827735A · Young et al. · 1998 [cited by applicant]
US 5827740A · Pittenger · 1998 [cited by applicant]
US 5827897A · Ailhaud et al. · 1998 [cited by applicant]
US 5854292A · Ailhaud et al. · 1998 [cited by applicant]
US 5906934A · Grande et al. · 1999 [cited by applicant]
US 5908784A · Johnstone et al. · 1999 [cited by applicant]
US 5937863A · Knowlton · 1999 [cited by applicant]
US 5968356A · Morsiani et al. · 1999 [cited by applicant]
US 6200606B1 · Peterson et al. · 2001 [cited by applicant]
US 6261549B1 · Fernandez et al. · 2001 [cited by applicant]
US 6316247B1 · Katz et al. · 2001 [cited by applicant]
US 6391297B1 · Halvorsen · 2002 [cited by applicant]
US 6429013B1 · Halvorsen et al. · 2002 [cited by applicant]
US 6478966B2 · Zhou et al. · 2002 [cited by applicant]
US 6544788B2 · Singh · 2003 [cited by applicant]
US 6555374B1 · Gimble et al. · 2003 [cited by applicant]
US 6777231B1 · Katz et al. · 2004 [cited by applicant]
US 6841150B2 · Halvorsen et al. · 2005 [cited by applicant]
US 6852533B1 · Rafii et al. · 2005 [cited by applicant]
US 7001746B1 · Halvorsen et al. · 2006 [cited by applicant]
US 7033587B2 · Halvorsen et al. · 2006 [cited by applicant]
US 7078230B2 · Wilkison et al. · 2006 [cited by applicant]
US 7078232B2 · Konkie et al. · 2006 [cited by applicant]
US 7179649B2 · Halvorsen · 2007 [cited by applicant]
US 7266457B1 · Hickman · 2007 [cited by applicant]
US 7294334B1 · Michal et al. · 2007 [cited by applicant]
US 7361368B2 · Claude et al. · 2008 [cited by applicant]
US 7390484B2 · Fraser et al. · 2008 [cited by applicant]
US 7429488B2 · Fraser et al. · 2008 [cited by applicant]
US 7470537B2 · Hedrick et al. · 2008 [cited by applicant]
US 7473420B2 · Fraser et al. · 2009 [cited by applicant]
US 7501115B2 · Fraser et al. · 2009 [cited by applicant]
US 7514075B2 · Hedrick et al. · 2009 [cited by applicant]
US 7531355B2 · Rodriguez et al. · 2009 [cited by applicant]
US 7572236B2 · Quick et al. · 2009 [cited by applicant]
US 7582292B2 · Wilkison et al. · 2009 [cited by applicant]
US 7585670B2 · Hedrick et al. · 2009 [cited by applicant]
US 7595043B2 · Hedrick et al. · 2009 [cited by applicant]
US 7622108B2 · Collins et al. · 2009 [cited by applicant]
US 7641643B2 · Michal et al. · 2010 [cited by applicant]
US 7651684B2 · Hedrick et al. · 2010 [cited by applicant]
US 7659118B2 · Furcht et al. · 2010 [cited by applicant]
US 7670596B2 · Collins et al. · 2010 [cited by applicant]
US 7687059B2 · Fraser et al. · 2010 [cited by applicant]
US 7708152B2 · Dorian et al. · 2010 [cited by applicant]
US 7727763B2 · McKenna, Jr. et al. · 2010 [cited by applicant]
US 7732190B2 · Michal et al. · 2010 [cited by applicant]
US 7744869B2 · Simon · 2010 [cited by applicant]
US 7749741B2 · Bullen et al. · 2010 [cited by applicant]
US 7771716B2 · Hedrick et al. · 2010 [cited by applicant]
US 7780649B2 · Shippert · 2010 [cited by applicant]
US 7780860B2 · Higgins et al. · 2010 [cited by applicant]
US 7789872B2 · Shippert · 2010 [cited by applicant]
US 7794449B2 · Shippert · 2010 [cited by applicant]
US 7887795B2 · Fraser et al. · 2011 [cited by applicant]
US 7901672B2 · Fraser et al. · 2011 [cited by applicant]
US 9206387B2 · Llull et al. · 2015 [cited by applicant]
US 9260697B2 · Cimino et al. · 2016 [cited by applicant]
US 9296984B2 · Cimino et al. · 2016 [cited by applicant]
US 9907883B2 · Llull et al. · 2018 [cited by applicant]
US 9909094B2 · Cimino et al. · 2018 [cited by applicant]
US 9909095B2 · Cimino et al. · 2018 [cited by applicant]
US 9950015B2 · Cimino et al. · 2018 [cited by applicant]
US 10138457B2 · Cimino et al. · 2018 [cited by applicant]
US 10336980B2 · Cimino et al. · 2019 [cited by applicant]
US 10898524B2 · Cimino et al. · 2021 [cited by applicant]
US 11261418B2 · Cimino et al. · 2022 [cited by applicant]
US 11649427B2 · Cimino et al. · 2023 [cited by applicant]
US 11666605B2 · Cimino et al. · 2023 [cited by applicant]
US 11732233B2 · Cimino et al. · 2023 [cited by applicant]
US 11898138B2 · Cimino · 2024 [cited by examiner]
US 20010030152A1 · Wright et al. · 2001 [cited by applicant]
US 20010033834A1 · Wilkison et al. · 2001 [cited by applicant]
US 20020076400A1 · Katz et al. · 2002 [cited by applicant]
US 20020119126A1 · Halvorsen · 2002 [cited by applicant]
US 20030082152A1 · Hedrick et al. · 2003 [cited by applicant]
US 20030161817A1 · Young et al. · 2003 [cited by applicant]
US 20030211602A1 · Atala · 2003 [cited by applicant]
US 20040067218A1 · Casteilla et al. · 2004 [cited by applicant]
US 20040097867A1 · Fraser et al. · 2004 [cited by applicant]
US 20040171146A1 · Katz et al. · 2004 [cited by applicant]
US 20050048034A1 · Fraser et al. · 2005 [cited by applicant]
US 20050076396A1 · Katz et al. · 2005 [cited by applicant]
US 20050153442A1 · Katz et al. · 2005 [cited by applicant]
US 20050282275A1 · Katz et al. · 2005 [cited by applicant]
US 20060051865A1 · Higgins et al. · 2006 [cited by applicant]
US 20060240546A1 · Goodwin et al. · 2006 [cited by applicant]
US 20070225665A1 · Perez-Cruet et al. · 2007 [cited by applicant]
US 20080014181A1 · Ariff et al. · 2008 [cited by applicant]
US 20080050275A1 · Bischof et al. · 2008 [cited by applicant]
US 20080319417A1 · Quijano et al. · 2008 [cited by applicant]
US 20090042267A1 · Park · 2009 [cited by applicant]
US 20100055087A1 · Higgins et al. · 2010 [cited by applicant]
US 20100285521A1 · Vossman et al. · 2010 [cited by applicant]
US 20100285588A1 · Stubbers et al. · 2010 [cited by applicant]
US 20110117650A1 · Riordan · 2011 [cited by applicant]
US 20120003733A1 · Gueneron · 2012 [cited by applicant]
US 20120214659A1 · Do et al. · 2012 [cited by applicant]
EP 0512769A2 · 1992 [cited by applicant]
JP 2009189282A · 2009 [cited by applicant]
JP 2011125813A · 2011 [cited by applicant]
JP 2013507983A · 2013 [cited by applicant]
WO 2010100212A1 · 2010 [cited by applicant]
WO 2011052946A2 · 2011 [cited by applicant]
WO 2012006587A2 · 2012 [cited by applicant]
WO 2013106655A1 · 2013 [cited by applicant]
WO 2014039697A1 · 2014 [cited by applicant]
WO 2014110448A1 · 2014 [cited by applicant]
Fodor et al.; Adipose Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint; Aesthtic Surgery Journal; 2016; vol. 36(2); pp. 229-236. [cited by applicant]
Garza et al.; “Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee: A Feasibility and Safety Study”; Journal of Regenerative Medicine; 2015; vol. 4:1; 6 pgs. [cited by applicant]
Koh et al.; “Infrapatellar fat pad-derived mesenchymal stem cell therapy for kneee osteoarthritis”; The Knee; 2012; vol. 19; pp. 902-907. [cited by applicant]
Koh et al.; “Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis”; Knee Surgery, Sports Traumatology, Arthroscopy; vol. 23(5); 2015; pp. 1308-13… [cited by applicant]
Koh et al.; “Mesenchymal Stem Cell Injections Improve Symptoms of Knee Osteoarthritis”; Arthroscopy: The Journal of Arhtroscopic and Related Surgery; 2013; vol. 29(4); pp. 748-755. [cited by applicant]
Michalek et al.; “Autologous adipose tissue-derived stromal vascular fraction cells applicaiton in patients with osteoarthritis”; Cell Transplantation; Cognizant Communication Corporation; 2015; 36 pgs. [cited by applicant]
Pak; “Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series”; Journal of Medical Case Reports; 2011; vol. 5:296; 8 p… [cited by applicant]
Pak et al; “Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints”; BMC Musculoskeletal Disorders; 2013; vol. 14;337; 8 pgs. [cited by applicant]
Lindroos et al., “The Potential of Apidose Stem Cells in Regenerative Medicine,” Stem Cell Rev and Rep (2011) 7:269-291, Springer Science+Business Media, LLC, published online Sep. 2010, pp. 269-291. [cited by applicant]
Pham et al., “Transplantation of Nonexpanded Adipose Stromal Vascular Fraction and Platelet-Rich Plasma for Articular Cartilage Injury Treatment in Mice Model,” Hindawi Publishing Corporation, Journal of Medical Enginee… [cited by applicant]
Desando et al., “Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model,” Arthritis Research & Therapy 2013, 16 pgs. [cited by applicant]
Toghraie et al., “Scaffold-free Adipose-derived Stem Cells (ASCs) Improve Experimentally Induced Osteoarthritis in Rabbits,” Archives of Iranian Medicine, vol. 15, No. 8, Aug. 2012, pp. 495-499. [cited by applicant]
English et al., “A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis,” Rheumatology Advance Access, published Sep. 2007, 8 pgs. [cited by applicant]